Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in korean patients with mild to moderate hypertension and dyslipidemia: An 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from daewoong)

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 2599-2609

  Park, Jin Sun ^a   Shin, Joon Han ^a   Hong, Taek Jong ^b   Seo, Hong Seog ^c   Shim, Wan Joo ^d   Baek, Sang Hong ^e   Jeong, Jin Ok ^f   Ahn, Youngkeun ^g   Kang, Woong Chol ^h   Kim, Young Hak ⁱ   Kim, Sang Hyun ^j   Hyon, Min Su ^k   Choi, Dong Hoon ^l   Nam, Chang Wook ^m   Park, Tae Ho ⁿ   Lee, Sang Chol ^o   Kim, Hyo Soo ^p  

^a Ajou University School of Medicine   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d College of Medicine   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f Chungnam National University College of Medicine   (South Korea)

^g Chonnam National University Medical School   (South Korea)

^h Gachon University   (South Korea)

ⁱ University of Ulsan College of Medicine   (South Korea)

^j Seoul National University Boramae Hospital   (South Korea)

^k Soonchunhyang University College of Medicine   (South Korea)

^l Yonsei University College of Medicine   (South Korea)

^m Dongsan Medical Center   (South Korea)

ⁿ Dong A University College of Medicine   (South Korea)

^o Sungkyunkwan University School of Medicine   (South Korea)

^p Seoul National University Hospital   (South Korea)

more..

Author keywords

Dyslipidemia; Fixed dose combination therapy; Hypertension; Olmesartan medoxomil; Rosuvastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; CREATININE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLMESARTAN; OLMESARTAN MEDOXOMIL PLUS ROSUVASTATIN; ROSUVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; DRUG COMBINATION;

ADULT; ARTICLE; COMBINATION DRUG THERAPY; CONTROLLED STUDY; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSLIPIDEMIA; FACTORIAL DESIGN; FEMALE; FIXED DOSE COMBINATION THERAPY; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOUTH KOREA; TREATMENT OUTCOME; CLINICAL TRIAL; DRUG COMBINATION; DYSLIPIDEMIAS; MIDDLE AGED;

ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OLMESARTAN MEDOXOMIL; REPUBLIC OF KOREA; ROSUVASTATIN CALCIUM;

EID: 84983354438     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S112873     Document Type: Article

References (22)

1. Kannel WB. Risk stratification in hypertension: new insights from the Framingham study. Am J Hypertens. 2000;13(1 Pt 2):3S–10S.
2. Nickenig G. Should angiotensin II receptor blockers and statins be combined? Circulation. 2004;110(8):1013–1020.
3. O’Meara JG, Kardia SL, Armon JJ, Brown CA, Boerwinkle E, Turner ST. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med. 2004;164(12):1313–1318.
4. Stamler J, Wentworth D, Neaton JD. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the multiple risk factor intervention trial. Am J Med. 1986;80(2A):33–39.
5. Castelli WP, Anderson K. A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham study. Am J Med. 1986;80(2A):23–32.
6. Emberson J, Whincup P, Morris R, Walker M, Ebrahim S. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J. 2004;25(6):484–491.
7. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet. 2005;365(9457):434–441.
8. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165(10):1147–1152.
9. Roh H, Son H, Lee D, Chang H, Yun C, Park K. Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects. Clin Ther. 2014;36(8):1159–1170.
10. Son H, Roh H, Lee D, Chang H, Kim J, Yun C, Park K. Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects. Clin Ther. 2013;35(7):915–922.
11. Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens. 2007;25(7):1327–1336.
12. Brunner HR. Olmesartan medoxomil: current status of its use in monotherapy. Vasc Health Risk Manag. 2006;2(4):327–340.
13. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103(6):904–912.
14. Prasad A, Tupas-Habib T, Schenke WH, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation. 2000;101(20):2349–2354.
15. Klingbeil AU, John S, Schneider MP, Jacobi J, Handrock R, Schmieder RE. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens. 2003;16(2):123–128.
16. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152–160.
17. Schwartz GG, Bolognese MA, Tremblay BP, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J. 2004;148(1):e4.
18. Werner N, Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol. 2002;97(2):105–116.
19. Wassmann S, Nickenig G. Interrelationship of free oxygen radicals and endothelial dysfunction–modulation by statins. Endothelium. 2003;10(1):23–33.
20. Sowers JR. Effects of statins on the vasculature: Implications for aggressive lipid management in the cardiovascular metabolic syndrome. Am J Cardiol. 2003;91(4A):14B–22B.
21. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation. 2002;105(3):393–396.
22. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulation. Circulation. 2002;105(4):530–536.